|

SHR-9839 Clinical Trials

3 actively recruiting trials

Pipeline

Phase 1: 1Phase 1/2: 2

Top Sponsors

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.2
  • Shanghai Hengrui Pharmaceutical Co., Ltd.1

Indications

  • Cancer3
  • Non-small Cell Lung Cancer (NSCLC)1
  • Advanced Solid Tumors1
  • Advanced Solid Tumor1
  • Lung Cancer1

Other3 trials

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Phase 1/2
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
Phase 1/2
The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.